^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Melanoma
    Drug:temuterkib (LY3214996) (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

    Excerpt:
    ...- Part E: Metastatic BRAF V600E colorectal cancer....
    Trial ID:
    NCT02857270
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Neuro Oncol
    Title:

    The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis

    Published date:
    12/22/2023
    Excerpt:
    We found that dual treatment with LY321 and anti-PD-1 significantly improved overall survival in two BRAFV600E-mutant murine melanoma models...Combined ERK and PD-1 inhibition is a promising therapeutic approach, worthy of further investigation for patients with melanoma BM.
    Secondary therapy:
    PD1 inhibitor
    DOI:
    https://doi.org/10.1093/neuonc/noad248